The kidney controls systemic calcium and phosphate levels and disturbances of its control mechanisms can lead to a variety of diseases. The insulin-sensitizing adipokine adiponectin is renoprotective and accelerates functional recovery following renal injury. However, unlike other adipokines, adiponectin is reduced in obesity. High adiponectin levels are also correlated with bone loss, suggestive of an additional action in mineral metabolism. Using knockout, wildtype, and adiponectin overexpressing transgenic mice, we sought to identify the mechanistic basis for adiponectin's ability to regulate calcium and phosphate balance at the level of the kidney. Adiponectin knockout mice exhibited lower serum calcium, lower urinary calcium excretion and markedly lower serum fibroblast growth factor 23 (FGF23) levels, although circulating klotho concentrations were significantly higher than in wildtype littermates. The transgenic mice exhibited lower bone mass and strength, particularly compared to adiponectin knockout mice. The transgenic mice were hyper-responsive to 2% phosphate-enriched diet, exhibiting 2-fold higher serum FGF23 and concomitantly higher fractional phosphate excretion. These mice also excreted more calcium with calcium-enriched diet and had less renal klotho protein expression. In contrast, the knockout mice exhibited a smaller increase in FGF23 and maintained elevated klotho levels on both mineral challenges. Kidney-specific adiponectin expression in doxycycline-inducible adiponectin mice and adiponectin addition in vitro confirmed adiponectin's ability to reduce tubular epithelial cell klotho secretion. Thus, adiponectin alters calcium and phosphate balance and renal mineral excretion, in part, through klotho. This work highlights the profound effects of adipose tissue on renal function and has identified a new mechanism by which adiponectin may regulate bone mass.
INTRODUCTION
The widespread increase in incidence of obesity has presented an opportunity and urgency for understanding the pathophysiology associated with adipose tissue. An array of obesityrelated co-morbidities has been attributed to dysfunctional adipose tissue and changes in proteins from the adipocyte secretome, termed adipokines. 1 In contrast to most adipokines that are increased with obesity and drive pro-inflammatory and insulin-resistant systemic phenotypes, adiponectin is highly cytoprotective and insulin-sensitizing, but its levels are paradoxically reduced with increased adipose mass leading to a loss of its protective effects with expanding adiposity. 2 Adiponectin levels are often inversely correlated with severity of disease states in mouse models and in human population studies. 3 This relationship goes beyond mere association and represents a cause/effect relationship, since adiponectin knockout (KO) mice are metabolically challenged under most experimental interventions and both adiponectin treatments and over-expression in mice provide beneficial effects. [4] [5] [6] Two chronic clinical conditions that present a quandary of elevated adiponectin levels in a pathologic state are chronic kidney disease (CKD) and osteoporosis.
Adiponectin exerts positive effects in kidney health in multiple murine models. Adiponectin KO (APN KO) mice are more prone to fibrosis and proteinuria following renal injury. 7, 8 Adenoviral expression in APN KO mice or transgenic overexpression of adiponectin rescued renal function and conferred protection from chronic injury. 9 Intravenous adiponectin administration into APN KO mice identified tubular epithelial cells as an adiponectin target which is compatible with the adiponectin receptor 1 being ubiquitously expressed in renal tubular cells. [10] [11] [12] Elevated adiponectin in chronic kidney disease (CKD) should theoretically provide a positive impact on renal health. The causes for elevated adiponectin in CKD have been proposed to be due to potential uremic effects on adipose tissue increasing secretion rather than changes in renal clearance. [13] [14] [15] Direct actions of adiponectin in the kidney are likely to be mechanistically diverse, similar to the array of beneficial signaling effects noted across other tissues.
In osteoporosis, the role and mechanisms of action of adiponectin in bone loss are better defined than in CKD, with postulated direct effects of adiponectin on bone. Not only do adiponectin levels clinically correlate with reduced bone mineral density (BMD), but thiazolidinedione drugs, activators of the nuclear receptor PPARγ, which induce their insulin-sensitizing effects partially through elevating adiponectin, are also associated with bone loss. [16] [17] [18] [19] [20] Adiponectin overexpressing transgenic mice exhibit reduced BMD with age compared to wild type. APN KO mice are at least partially protected from age-related bone loss. 18, [21] [22] [23] Results in these mouse models have, however, demonstrated variable adiponectin effect size, possibly due to the expression method employed or deletion strategy used. 18, 23 Mechanistically, these effects have thus far been linked to changes in energy expenditure and through direct signaling in bone cells driving a resorption phenotype. 18, 20, 24 The kidney plays a critical role in systemic mineral balance through a bone-parathyroid gland-kidney based endocrine axis of the circulating hormones FGF23, parathyroid hormone (PTH), vitamin D and Klotho, respectively, that maintain external balance and blood levels of calcium and phosphate. 25 Much has been hypothesized about the interplay of adiponectin, vitamin D and PTH in energy and calcium balance, but few direct adiponectin-related mechanisms have been identified. 26, 27 Adiponectin action has been mechanistically tied to another endocrine factor, FGF21, and its co-receptor, beta-klotho in liver and adipose tissue. 28, 29 We therefore hypothesized that a relationship between adiponectin, bone-derived FGF23 and its kidney-based co-receptor alpha-Klotho (here simply referred to as Klotho) exists and may be responsible for the dysregulated calcium and phosphate balance observed under conditions of high adiponectin levels, thereby modulating the cytoprotective effects of Klotho, and contributing to bone disease in CKD.
We utilized adiponectin KO, wildtype, and transgenic overexpressing mice to characterize and quantify the impact of adiponectin levels on calcium and phosphate homeostasis. We also tested the effects of a dietary phosphate and calcium challenge in these various genetic backgrounds. In addition, mice with inducible local renal adiponectin overexpression allowed us to examine adiponectin effects restricted to the kidney. The in vivo studies were supplemented by direct in vitro measures of adiponectin addition to renal tubular epithelial cells. These experiments have identified that heightened adiponectin increases bone loss and calcium excretion and directly reduces Klotho release. These novel effects of adiponectin thus further highlight the emerging link between adipose tissue, metabolic health, CKD and bone maintenance.
RESULTS

Elevated adipocyte adiponectin expression leads to reduced bone density and reduced bone strength
Adiponectin overexpressing mice (APN-Tg) exhibit an increase in circulating adiponectin levels in a physiologically relevant range ( Fig. 1A) and thus provide a model with which to study the clinical impact of elevated adiponectin levels. As described previously, 4, 8, 30 there is no difference in body weight or in baseline urinary parameters, such as volume, pH or creatinine clearance (Supp. Fig. 1A -D).
Very high levels of adiponectin were associated with low bone mineral density in mice 18 . We assessed bone strength, mineral density, and turnover in the mouse lines expressing a range of adiponectin levels. In agreement with previous findings, 21 physiologically-relevant overexpression of adiponectin in male mice results in a modest, yet significant, decrease in bone parameters. Quantitation of microCT scans of L5-L6 lumbar vertebrae and femurs from these mice (Supp. Fig. 2A ; Supp Table 2 ) revealed no significant difference in bone mineral density ( Fig. 1B) , 21 but mice with adiponectin had significantly increased bone surface to volume ratios ( Fig. 1C ) and trabeculae number suggestive of less dense bone structure than APN KO mice. Bone volume to trabecular volume trended with adiponectin (Supp. Fig. 2B ) and trabeculae were significantly larger and more spaced (Supp. Fig. 2C , D) in APN KO mice. Similarly, the connective tissue mineral density of APN Tg mice was significantly reduced as compared to APN KO mice ( Fig. 1E ). Biomechanical analysis of the distal femurs from these mice demonstrated a significant difference across genotype in bending stiffness and deformation ( Fig. 1F , G). Peak loading was similar, though the fracture energy was significantly higher in APN KO mice (Supp. Fig 2E, F) . While these effects are modest, they do suggest a dysregulated mineral homeostasis associated serum adiponectin levels.
Relationship of adiponectin levels with mineral parameter and calciotropic and phosphaturic hormones
With accelerated bone loss over time in APN-Tg mice, we explored for changes in systemic mineral homeostasis starting with Ca 2+ . Serum Ca 2+ trends with adiponectin levels ( Fig. 2A ) with APN-Tg having significantly higher levels than APN KO mice. This same positive relationship is also present in the fractional excretion of Ca 2+ (FE Ca ) (Supp. Fig. 3A ). Linear regression analysis demonstrates a highly significant correlation of adiponectin levels with FE Ca in individual mice across the mouse lines ( Fig. 2B ). Thus the higher serum Ca 2+ in the higher adiponectin states is not due to renal Ca 2+ retention. In contrast to Ca 2+ , basal serum phosphate levels ( Fig. 2C ) and urinary fractional excretion of phosphate (FE Phos ; Fig. 2D ) are independent of adiponectin genotype (Supp. Fig. 3B ).
There are hormonal signaling axes communicating across multiple organs that regulate mineral balance through altering uptake, storage, and excretion of calcium and phosphate; Vitamin D, PTH, FGF23, and soluble Klotho are the key hormones of this tightly balanced regulatory network. 25 Each of these hormones was measured in mice expressing different levels of adiponectin. While each of these components exhibits a wide range of values, similar to the range for these parameters in human spot measurements, clear relationships of some of these levels with adiponectin are apparent. Active vitamin D (1,25-dhydroxyl vitamin D) levels ( Fig. 2E ) are not significantly different with varying adiponectin levels, nor are serum PTH concentrations ( Fig. 2F ). In contrast to PTH and active vitamin D, bonesecreted full-length FGF23 levels are significantly lower in APN-Tg mice ( Fig. 2G ), although levels are not higher in APN KO mice. Circulating Klotho levels, which are derived mostly from the renal cortex, 31 are elevated in mice lacking adiponectin ( Fig. 2H ). Adiponectin levels appear to establish different homeostatic set points for these hormones. We next sought to test these relationships by challenging the mice with a 2% phosphate diet that has served in the past as a model for driving changes in phosphaturic hormones. 32
Serum adiponectin does not confer protection from fibrosis induced by phosphate loading
The effect of adiponectin levels on recovery from partial nephrectomy in mice is well documented. 7 A high phosphate diet (2%) coupled with 5/6 nephrectomy-induced CKD in murine models results in renal and cardiac fibrosis, and soft tissue calcification, particularly if Klotho levels are low or absent. 32, 33 We utilized a 2% Pi diet to challenge the response in hormones governing renal phosphate and calcium balance and explore any difference in consequences in the three lines of mice. Post loading, a subgroup of mice was returned to normal Pi chow to assess any potential role of adiponectin in recovery.
A 2% Pi diet given over a sufficient period of time induces rather mild renal tubulointerstitial fibrosis in each of the mouse lines ( Fig. 3A) . Although no gross differences were apparent, quantitation of total kidney collagen content revealed less collagen in APN KO mouse kidneys after 2 months of 2% Pi diet ( Fig. 3B ). No significant recovery was noted in any of the adiponectin mouse lines following removal of high phosphate diet ( Fig.  3B ). In the absence of CKD, Pi diet resulted in minimal renal calcification; quantification of von Kossa positive area confirmed no significant histologic differences in mineralization (Supp. Fig. 4A , B). Cardiac fibrosis was also minimal and not appreciably different across the adiponectin mouse models, nor was there any change in total heart mass (Supp. Fig. 4C , D). No evidence of aortic mineralization was observed (data not shown).
Adiponectin alters hormone levels and renal mineral excretion upon P i challenge
Part of the fibrotic response to phosphate loading maybe mediated by the endocrine axis that regulates mineral excretion. 25 Adiponectin levels demonstrate a relationship with these hormones on normal chow diet, and in the context of the phosphate-driven fibrosis, conditions may further deteriorate with high adiponectin. We addressed renal mineral excretion during the high P diet, and the endocrine hormones that regulate this balance.
All models exhibited an increase in serum phosphate under high Pi challenge and were able to maintain steady serum Ca 2+ levels (Suppl. Fig. 5A, B ). As expected, the fractional excretion of Ca 2+ (FE Ca ) is significantly reduced in all mouse lines on Pi diet due to intestinal chelation of Ca 2+ . APN-Tg mice, however, excrete significantly more Ca 2+ than their wildtype littermates ( Fig. 4A ). Removal of the diet for one month restored FE Ca back to basal levels in all mice, wherein APN-Tg mice exhibited sustained heightened FE Ca . Concurrently, FE Phos was markedly elevated in all mice -a necessary and expected response to the Pi load -with APN-Tg mice excreting significantly more ( Fig. 4B ). Following return to chow diet, all mice leveled off to basal excretion levels. Phosphate challenge did induce a small reduction in circulating adiponectin levels in all mice (Suppl. Fig. 5C ).
Vitamin D levels were elevated on P i diet in all mouse lines ( Fig. 4C ). Serum levels went down to normal in KO and wildtype mice, but remained significantly higher than baseline in APN-Tg mice after return to normal chow diet for 1 month. Serum PTH concentrations were dramatically elevated in all mice on P i diet. APN KO mice, however, exhibited a significantly lower increase in PTH with levels less than 50% those of wildtype or APN-Tg mice ( Fig. 4D ). FGF23 levels, which were significantly lower in APN-Tg mice on normal chow diet, demonstrated an amplified response to Pi diet as compared to WT mice.
Interestingly, KO mice were significantly lower, establishing a clear correlation between adiponectin levels and FGF23 secretion in response to P i loading ( Fig. 4E ). Serum Klotho levels were lower on the high P i diet as we have observed before. APN-KO mice consistently demonstrated significantly higher Klotho in circulation ( Fig. 4F ). Urinary excretion of klotho was not different across the models (Suppl. Fig. 5D ).
RNA expression of Npt2a (Slc34a1, NaPi2a), the gene encoding the primary renal phosphate transporter, was reduced on Pi diet. Adiponectin had no effect with respect to Npt2a transcriptional regulation ( Fig. 4G ). Renal Klotho mRNA tended to be reduced, but mRNA expression for the FGF23 co-receptor for Klotho, FGFR1, was significantly elevated in APN-Tg kidneys. In KO mice, where FGF23 serum levels were lower, Fgfr1 expression was reduced relative to wildtype kidney RNA under Pi challenge.
Adiponectin levels alters Ca 2+ excretion and hormones upon Ca 2+ challenge
Phosphate loading identified that adiponectin levels impact phosphaturic hormones and impact phosphate excretion upon challenge. These mechanisms are inverse for calcium balance. We thus challenged the adiponectin mice with a 4% Ca 2+ diet for one week to determine if adiponectin levels similarly correlated with calcium excretion. High calcium significantly increased Ca 2+ fractional excretion as expected, but in an adiponectindependent manner. In APN KO mice, FE Ca was significantly less, while APN-Tg were significantly higher than wildtype mice ( Fig. 5A ). Fractional excretion of phosphate was accordingly reduced, but with no dependence on adiponectin ( Fig. 5B ). Short-term Ca 2+ loading increased 1,25-dihydroxy Vitamin D serum levels in APN-Tg mice (Fig. 5C ), and all mice exhibited dramatically reduced PTH levels ( Fig. 5D ). Similar to previous groups, we found significantly elevated FGF23 in APN-KO mice on equivalent chow diet; calcium loading reduced these levels in both APN-KO and APN-Tg mice (Fig. 5E ). As in all experiments, secreted klotho levels were significantly elevated when adiponectin was absent ( Fig. 5F ).
Cortical expression of mRNAs for Npt2a (Slc34a1, NaPi2a), klotho, and Fgfr1 were inverse of those of kidneys during phosphate loading. There was no change in Slc34a1 expression with calcium challenge, but klotho and Fgfr1 expression levels were significantly elevated in APN-KO mice as compared to wildtype mice ( Fig. 5G) .
A complex endocrine network governs systemic calcium balance. Adiponectin is part of this regulatory network. While our hormonal, functional and genetic feedback data implicate adiponectin in the process of renal mineral homeostasis in vivo, we sought to identify a more direct involvement of adiponectin on this network with additional experiments.
Adiponectin directly reduces FGF23 and Klotho secretion in vitro
Our data on the 2% Pi diet suggests that adiponectin's role may be at least partially through the FGF23-Klotho axis. To test this hypothesis, we utilized a novel model of inducible, kidney-specific adiponectin expression to test this in vivo, and in vitro experiments were performed to test direct cellular actions of adiponectin. Rutkowski 
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Model murine IDG-SW3 osteocytes demonstrated to secrete FGF23 were cultured as previously described. 34 Recombinant full-length murine adiponectin protein was applied to these cells in levels similar to the serum of APN-Tg mice. Adiponectin caused a significant reduction in FGF23 secretion ( Fig. 6A ). Treating the osteocytes with calcio-protein particles (CPP) to simulate Pi loading has been reported to stimulate FGF23 secretion, similar to osteocyte responses to pro-inflammatory stimuli. 34 Here, CPPs induced a significant FGF23 increase that was markedly reduced in the presence of adiponectin. These results mirrored baseline APN-Tg mice that have higher adiponectin and reduced inflammation; 4 
an in vivo
Pi challenge, however, is more complex with respect to the elevated FGF23 levels seen in APN-Tg mice. For example, CPP levels in KO mice were significantly higher (Supp. Fig  6A) and not accounted for in vitro.
Adiponectin's relationship to circulating Klotho levels was further examined in a series of in vitro and in vivo experiments. In vitro, MDCK cells, a canine renal tubular epithelial cell line that expresses and secretes Klotho, were transfected with a human ADIPOQ expression plasmid, but no change in Klotho secretion was detected. Similarly, transfection with plasmids that express either human adiponectin receptors 1 and 2, ADIPOR1 and ADIPOR2, failed to elicit a change in Klotho secretion ( Fig. 6B ). However, co-transfection of human ADIPOQ with either ADIPOR1 or ADIPOR2 together, however, induced a significant reduction in Klotho secretion. Similar results were also obtained with murine AdipoR1 and AdipoR2 transfected MDCK cells cultured in sera collected from KO, wildtype, and APN-Tg mice (Supp. Fig. 6B ). Canine Klotho (~130kDa versus ~135kDa murine) was reduced depending on adiponectin concentration and enhanced with APN receptor overexpression.
In serum measurements, APN KO mice consistently exhibited higher Klotho levels and renal cortical Klotho mRNA expression (Supp. Fig. 6B ). Klotho protein in the renal cortex was quantified and there was no difference between APN KO, wildtype, or APN-Tg mice on chow diet (Fig. 6C ). On P i diet, however, APN-Tg mice had significantly reduced renal klotho protein.
Renal tubule-specific expression of adiponectin
The cell culture studies support a direct action of adiponectin on osteocytes and renal epithelia. To further determine if this effect was specific to adiponectin signaling within the kidney, we crossed a novel model of doxycycline-inducible adiponectin expression, the TRE-adiponectin mouse, with a renal tubule-specific (KSP) promoter mouse, KSP-rtTA. 35 KSP-APN mice on a wildtype adiponectin background achieve markedly increased adiponectin expression when fed a doxycycline-containing chow diet (Fig. 6D, E) . Klotho protein levels in the renal cortex in KSP-APN mice were significantly reduced following induction of adiponectin expression ( Fig. 6F ) and FRS2 phosphorylation, a marker of downstream of Klotho-FGFR signaling, trended towards reduction (Supp. Fig. 6D ). Interestingly, serum Klotho levels in these mice were not reduced (Fig. 6G) ; akin to the observation that serum Klotho levels were not different in APN-Tg mice (Fig. 2H ).
We challenged these mice with dietary phosphate loading and induced adiponectin with a lower 200 mg/L doxycycline exposure. Mice positive for the KSP-APN transgene exhibited a significant reduction in serum Klotho compared to both standard chow and -rtTA littermates (Fig. 6G ). This protocol led to a surprisingly robust adiponectin-mediated FGF23 response as well ( Fig. 6H ). Kidney histology at 2 months revealed a clear increase in fibrosis in KSP-APN mice challenged with phosphate ( Fig. 6I) , commiserate with the reduced Klotho levels. To further isolate the effect of adiponectin to the kidney, KSP-APN mice were crossed to the adiponectin KO background, such that adiponectin production would be limited exclusively to the kidney upon doxycycline induction. Significantly lower serum Klotho levels were measured in KO-KSP-APN mice, further demonstrating that adiponectin reduces renal Klotho expression and secretion (Fig. 6E) . No significant effect on FGF23 was measured on chow diet in KO-KSP-APN mice (Suppl. Fig. 6E ). In total, adiponectin signaling reduces renal Klotho levels with local and systemic implications ( Fig. 7 ).
DISCUSSION
We have found that adiponectin levels impact systemic mineral balance and have profound effects on renal handling of a high phosphate challenge through the endocrine network of mineral metabolism. 25 Serum levels of adiponectin signal to multiple tissues to change the levels of phosphaturic hormones. Direct adiponectin action in the kidney reduces Klotho secretion, and systemically, it reduces FGF23 in the bone. A high calcium or high phosphate diet alters this balance: APN-Tg mice are more sensitive to phosphate-mediated FGF23 elevation, while effects in KO mice are likely to be mediated through heightened klotho levels. We observed increased serum calcium accompanied by increased calcium excretion from APN-Tg mice, an effect magnified with calcium loading, indicative of extra-renal (absorptive, resorptive, or both) origin of the higher serum calcium. The intestinal origin cannot be ascertained, but a bone resorptive mechanism is plausible given the bone phenotype in APN KO mice. 18, 21 Normally, calciotropic hormones should counterbalance any changes to maintain calcium stores, but adiponectin disrupts FGF23 and Klotho levels.
These studies thus identify adiponectin as a novel regulator of the kidney-bone endocrine signaling axis.
Increased circulating levels and systemic signaling of adiponectin have overwhelmingly identified the protein as a beneficial contributor to systemic homeostasis, exerting insulinsensitizing and anti-inflammatory effects that play a role in regulating human and rodent pathologies. 2 These positive effects are reduced in obesity when adiponectin levels are lower. Pathological conditions such as CKD where adiponectin levels are increased, thus, present a quandary as to what exactly is adiponectin's role in these conditions. 2, 13, 36, 37 Adiponectin is highly beneficial to renal function in experimental models 7-9 though some fibrosis models conflict with these findings. 38, 39 We demonstrate here that high adiponectin levels in the APN-Tg mouse regulates mineral metabolism through modulation of the endocrine axis of systemic calcium-phosphate balance.
Adiponectin reduces renal Klotho secretion. We confirmed this based on three fronts-in mice with a wide range of adiponectin levels, in mice with inducible kidney-specific adiponectin expression, and finally in cultured renal epithelial cells. The effects reported are adiponectin receptor-dependent. This lowering of Klotho by adiponectin may explain the dichotomous relationship we discovered regarding renal fibrosis. While adiponectin may exert its well-characterized protective and anti-fibrotic effects, renal fibrosis is highly dependent on Klotho levels. 32 Elevated Klotho in adiponectin KO mice may thus prove to be more protective locally, an effect that we measured with reduced matrix deposition and gene expression. Adiponectin may, therefore, be protective in some models but not others, depending on the role of klotho in the response. To that end, we found the wildtype mice were often worse off in mineral balance and in tissue pathology to phosphate loading challenge then either adiponectin KO mice with high klotho or APN-Tg mice with reduced klotho response. Further studies with genetic mouse models with manipulated Klotho levels will be interesting to assess this relationship further.
Another effect of adiponectin is the inhibition of FGF23. FGF23 is a member of the endocrine FGF family of proteins that signal through FGFR1, with the Klotho as co-factors. FGF19/15 (a human/mouse designation) and FGF21 requires beta-Klotho to signal and FGF23 requires alpha-Klotho (synonymous with Klotho). 25 The tissue distribution of the alpha vs. beta-Klotho proteins thus provides regulation as to the signaling tissues for the endocrine FGFs with adipose tissue serving as a primary site of FGF21 insulin-sensitizing action 40 and FGF23 signaling primarily in the kidney and parathyroid glands to regulate phosphate excretion. 25 A link between energy expenditure, metabolism, and bone mass certainly exists with adiponectin and endocrine FGFs potentially playing direct roles. 18, 41 Both increased FGF21 and adiponectin lead to bone loss in mice and adiponectin and thiazolidinedione drugs (which elevate adiponectin) are both linked to reduced bone mass and osteoporosis. 18, 21, 41 We found reduced FGF23 in APN-Tg mice and elevated levels in APN KO mice on normal chow, a result similar to one clinical study that found an inverse relationship between these hormones. 42 We also found that adiponectin directly reduces FGF23 in osteocytes. When challenged with a phosphate diet, however, both APN-Tg and KSP-APN mice exhibited exaggerated FGF23 production. While the effect in the APN-Tg mice can be explained by direct action on the osteocytes, the KSP-APN result are particularly interesting because it suggests that in addition to the direct effect on osteocytes, FGF23 levels may be driven by other factors initiating from the kidney that are downstream from adiponectin. This mouse model will provide an excellent opportunity to examine these factor(s).
The phosphaturia in response to dietary phosphate is much exaggerated in APN-Tg mice. This can be explained by the higher FGF23, higher PTH, or both in response to the high phosphate diet in higher APN states. Interestingly, the higher FE Phos did not result in lower serum P i levels in the APN-Tg mice. The possibility of intestinal and/or bone contributions cannot be ruled out.
In summary, we identified that the adipokine adiponectin plays a significant role in the regulation of mineral homeostasis. Adiponectin levels correlate with mineral excretion and adiponectin signaling directly causes a reduction in osteocyte FGF23 secretion and renal tubular epithelial cell Klotho secretion. Previously identified mechanisms of adiponectin action in regulating bone mass are also likely to be important; however, to date none have linked renal control of mineral homeostasis with adiponectin. We have therefore identified a novel link between adiponectin signaling and endocrine mineral regulation. The proposed model is summarized in Figure   Rutkowski 
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METHODS
Mouse Models
Adiponectin knock-out (APN-KO), wildtype (WT), and aP2-promoter-driven delta-gly adiponectin overexpressing (APN-Tg) male mice were used for all experiments on a full FVB background. The generation and basic metabolic characterization of adiponectin KO and APN-Tg mice on a FVB-background were previously described. 6, 30 Mice were provided ad libitum diet (Harlan Teklad 7001) and water throughout their lifetimes. For phosphate loading, mice were switched to 2% phosphate (P i )-containing chow (Harlan Teklad TD.08020) at 2 months of age and maintained on the diet for 2 months, when mice were assessed. The post-phosphate recovery groups were placed back on standard chow diets for another month. For calcium loading, mice were switched to a 4% total Ca2+-chow (71g calcium tetrahydrate + 429g Harlan Teklad 2016 chow) for one week and maintained on that diet during fluid collection. Blood and urine collection and tissue analyses were performed on all mice at approximately 5 months of age.
Generation of an inducible adiponectin expressing mouse
To generate a doxycycline-inducible adiponectin overexpressing mouse model, the coding sequence for full length murine adiponectin was cloned from murine subcutaneous adipose tissue cDNA; a KOZAK sequence of 5′-GCCGCCACC-3′ was placed in front of the adiponectin start codon and this cDNA was cloned into a vector featuring a "tight" pTREpromoter (Clontech, Mountain View, CA) and the rabbit β-globin 3′UTR at the 3' end. Following linearization, TRE-adiponectin DNA was injected into C57/Bl6 embryos by the Transgenic Core at UT Southwestern Medical Center. Positive pups were screened for both tight repression at baseline and doxycycline inducibility in adipose tissue when crossed with the adiponectin-rtTA mouse line 43 . A functional line was identified and then crossed with the kidney-specific protein (KSP)-rtTA mouse line for renal tubular epithelial cell-specific expression. 35 Chow containing 600 mg/kg doxycycline (Bio-Serv, Flemington, NJ) was supplied ad libitum for 7 days prior to sampling to induce adiponectin expression. In all TRE-adiponectin experiments, littermates were used +/− the KSP-rtTA transgene and all of the mice were placed on doxycycline to eliminate effects specific to the antibiotic.
Urine, blood, and tissue collection
After experimental diet exposure (2 months P i chow, 2 months P i + 1 month recovery, or standard chow throughout), mice were weighed and placed into individual cages (Tecniplast USA; Harvard Apparatus, Holliston, MA) with ad libitum access to their respective diets in powdered form and water for a 48-hour acclimatization period followed by a 48-hour (9 a.m. -9 a.m.) collection period. Urine samples were maintained under 5 mm thickness of mineral oil to preserve pH. At the end of urine collection, all mice were euthanized by isofluorance overdose and blood collected. 48-hour urine volumes were measured and urine samples were maintained at 4°C until processing. Mouse tissues were weighed and either flash-frozen in liquid nitrogen and stored at −80°C for biochemical and genetic analyses, or fixed in 10% buffered formalin overnight for histology.
Urine and serum analyses
Urine and serum creatinine were measured by capillary electrophoresis as previously described. 8 Urine calcium was measured on the Agilent Technology SPS3 by atomic absorbance of nebulized calcium atoms and urinary phosphate was measured on the COBAS MIRA Plus by a colorimetric assay detecting phosphate. Urine protein concentrations were quantitated by BCA Assay (Thermo Scientific, Rockford, IL) using a 1:40 dilution in PBS; values are expressed as a ratio to creatinine. 48-hour urine volumes were used for clearance rates values.
Serum calcium and phosphate were measured by Vitros (Ortho Clinical Diagnostics, Raritan, NJ). 1,25-Dihydroxy vitamin D concentrations were measured by enzyme immunoassay (Immunodiagnostic Systems Inc., Scottsdale, AZ). FGF-23 serum concentrations were measured by a mouse-specific ELISA (serum: EMD Millipore, Billerica, MA; urine: Kainos Laboratories, Inc., Tokyo, Japan). Serum PTH was also measured by ELISA (Immuntopics International, San Clemente, CA). Serum and urine soluble Klotho concentrations were quantified through immunoprecipitation followed by immunoblotting as previously described. 44
Histology and immunofluorescence
Following 24-hours in formalin, fixed tissues were rinsed and stored in 70% ethanol until processing and paraffin embedding. 3 µm-thick sections were cut from all tissues. Kidneys and hearts were sectioned sagitally and aortas were grossed and sectioned so as to crosssection both the ascending and decending aorta. Tissues were stained by trichrome to visualize fibrosis and Von Kossa for mineralization. Images of sections were captured using an Olympus FSX100 Imaging System.
For immunofluorescence, sections were deparaffinized, rehydrated and subjected to 10minute citrate buffer (Vector Labs, Burlington, CA) antigen retrieval. Tissues were labeled with primary antibodies to murine adiponectin (AF1119; R&D Systems). Secondary detection was by Alexafluor488 or 594-labeled donkey or chicken antibodies (Life Technologies, Carlsbad, CA). Immunofluorescence was imaged using a Zeiss AxioObserver fluorescence microscopy system and Hammamatsu C11440 camera.
Kidney collagen content
Kidney tissues (approximately ½ of a kidney cut transverse) were weighed wet then heated for 2 hours at 80 °C under vacuum and reweighed to determine dry weight. Tissue hydroxyproline composition was measured as previously detailed using all chemicals and trans-4-hydroxy-L-proline standard from Sigma (Sigma, St. Louis, MO) and presented on a µg collagen/mg dry tissue weight assuming that collagen is 12.5% hydroxyproline. 45
Protein extraction and quantification
A portion of renal cortex (30-60 mg) was homogenized in 500 µL TNET buffer (50 mM Tris, 150mM NaCl, 1mM EDTA, and 1% Triton X-100 (all Sigma)) containing a protease inhibitor cocktail (Calbiochem, Billerica, MA). Protein concentrations were quantified by BCA Assay and samples were normalized to the minimum sample concentration. 5×
Laemmli sample buffer containing DTT was added and samples were heated at 95°C for 5 minutes. 5 µg sample was loaded onto Bio-Rad Criterion TGX gels and separated by gel electrophoresis. Gels were blotted onto nitrocellulose membranes; proteins were identified by primary antibodies against Klotho (AF1819; R&D Systems and KM2076; Trans Genic Inc. Kobe, Japan), pFRS2 (Cell Signaling Technology, Danvers, MA), FRS2 (R&D Systems), and b-actin (Cell Signaling Technology) and detected by IRDye 800CW and 700CW labeled secondary antibodies (LI-COR Biosciences, Lincoln, NE) scanned on a LI-COR Odyssey imaging system. Immunoblot band intensities were quantified using LI-COR Odyssey software.
RNA extraction and gene expression analysis
RNA was isolated from a small portion of renal cortex (30-60mg) using the Qiagen RNeasy Mini Kit according to the manufacturer's protocol (Qiagen N.V., Valencia, CA). 950 ng of RNA was reverse transcribed using the Bio-Rad iScript cDNA Synthesis kit according to the kit instructions. Power SYBER Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) was used for the quantitative PCR reactions; reactions were run and quantified on an Applied Biosystems 7900 lightcycler. Actb was used as an endogenous control. Primer sequences for all genes are listed in Supplemental Table 1 .
Tissue Culture
Madin-Darby Canine Kidney (MDCK) epithelial cells were cultured in high glucose DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin. For the mouse sera experiment, sera were collected under sterile conditions, added to basal DMEM to 10% concentration, and sterile (0.22 µm) filtered. Full medium was removed, cells were rinsed twice with basal DMEM, and 10% mouse sera media added overnight in 48-well plates in duplicate. Murine and canine Klotho were measured in the media by immunoblot as described. For transfection experiments, MDCK cells were transfected with previously generated GFP, AdipoQ, and AdipoR pcDNA3.1 expression plasmids 5 using polyethylenimine (Sigma) with approximately 0.1 µg DNA/well in 24-well plates. Media was changed after 12 hours with full DMEM and cells incubated for 24 hours before a subsequent media change. Media was collected 24 hours later and canine Klotho was measured as above.
IDG-SW3 osteocytes 46 were cultured for 28 days and verified for Dmp1-GFP expression to confirm differentiation. Calcium phosphate crystals were prepared and added at approximately 50 µg/well. HEPES buffer +/− 80 µg/mL recombinant murine adiponectin (final concentration of 8 µg/mL; prepared as previously described 11 ) was added to the cells in duplicate for 2 hours and the media collected. FGF23 was quantified by ELISA (Kainos).
Micro-CT of femurs and vertebrae
Femurs and L6 vertebrae were maintained in 20% EtOH at −20°C until scanning and testing. Bones were allowed to reach room temperature before scanning at 12µm isotropic voxel size using an eXplore Locus SP CT Scanner (GE Healthcare, London, Ontario, Canada). Reconstructed volumes were processed using Microview software (GE Healthcare) and analyzed for bone mineral density (BMD), bone volume fraction (BV/TV) and trabecular morphometry including trabecular thickness (Tb.Th), trabecular separation (Tb.Sp) and trabecular number (Tb.N).
Biomechanical analysis of femurs and vertebrates
Standard protocols were used to o determine the bone biomechanical properties. 47 Briefly, femurs and vertebrae were rehydrated in PBS and preconditioned with 20 cycles of bending (0.2mm) load using a material testing system (Bose Electroforce model # 3230, Eden Prairie, MN). The samples were then loaded to failure by three-point bending (3mm and 3mm apart) under displacement control (0.03 mm/sec). Yield Load (N), Fracture Load (N), Fracture Energy (mJoule), and Bending Stiffness (N/mm) were calculated from the linear region of displacement-load curve.
Statistics and data presentation
Due to the variability of endocrine hormones, each group of APN KO, WT, or APN-Tg mice included 20 animals in P i challenges to ensure adequate power to discern biologic differences. Calcium loading experiments utilized 4 mice in all groups except wildtype chow, which only had 3 mice. Fluid collections for each mouse, however, provided limited volumes from which to assess each measure. Priority was given to endocrine hormones of interest: vitamin D, PTH, FGF23, and Klotho. Every available sample was measured and graphed as individual mouse data points with a mean +/− SE. Bar graphs equivalently demonstrate mean +/ SD for in vitro experiments with fewer measurements. In graphs wherein adiponectin level was the only variable one-way ANOVA with Tukey post-hoc analysis was performed in GraphPad Prism software. In experiments where both adiponectin and diet were independent variables, two-way ANOVA were performed with Tukey post-hoc analysis of multiple comparisons indicated for significance. For tissue culture experiments, Bonferroni post hoc analysis was used to compare all tests to the equivalent null GFP vector samples. In the figures, significance by the convention of: * = p<0.05, ** = 0.01>p>0.001, and *** = p<0.001. In APN-Tg mice, exhibit low FGF23 levels despite bone loss. APN-KO mice have increased klotho and bone mass at baseline. Under phosphate challenge, FGF23 and PTH responses are muted in KO mice with higher klotho while renal adiponectin signaling reduces klotho and helps to drive a heightened hormonal response; the inverse occurs with calcium challenge. Solid black connecting arrows indicate the direction of signaling under normal or low adiponectin levels. Red blocked arrows from the adipose tissues are pathways inhibited by increased adiponectin action. Adiponectin thus pushes the balance towards increased calciuria.
